Bolus ingestion of individual branched-chain amino acids alters plasma amino acid profiles in young healthy men by Takuya Matsumoto et al.
a SpringerOpen Journal
Matsumoto et al. SpringerPlus 2014, 3:35
http://www.springerplus.com/content/3/1/35RESEARCH Open AccessBolus ingestion of individual branched-chain
amino acids alters plasma amino acid profiles in
young healthy men
Takuya Matsumoto1, Koichi Nakamura2, Hideki Matsumoto3, Ryosei Sakai3, Tomomi Kuwahara3, Yoshihiro Kadota2,
Yasuyuki Kitaura2, Juichi Sato1 and Yoshiharu Shimomura2*Abstract
Physiological conditions in humans affect plasma amino acid profiles that might have potential for medical use.
Because the branched-chain amino acids (BCAAs) leucine, isoleucine and valine are used as medicines and
supplements, we investigated the acute effects of individual BCAAs (10–90 mg/kg body weight) or mixed BCAAs
ingested as a bolus on plasma amino acid profiles in young healthy men. Plasma leucine levels rapidly increased
and peaked around 30 min after leucine ingestion. Concentrations of plasma isoleucine, valine and phenylalanine
subsequently decreased after ingestion, and those of methionine and tyrosine tended to decrease. The effects of
ingested leucine on other plasma amino acids were biphasic, being higher at lower doses (10–20 mg/kg body
weight). Isoleucine or valine intake also caused corresponding plasma amino acid concentrations to rapidly elevate,
and peaks at 30–40 min after ingestion were much higher than that of plasma leucine after leucine ingestion.
However, the increase in plasma isoleucine and valine concentrations essentially did not affect those of other
plasma amino acids. The rate of decline among peak plasma BCAA concentrations was the highest for leucine,
followed by isoleucine and valine. Oral mixed BCAAs promoted the decline in plasma isoleucine and valine
concentrations. These results suggest that plasma leucine is a regulator of the plasma concentrations of BCAAs,
methionine and aromatic amino acids.
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Leucine, isoleucine and valine have branched-chain
residues and are thus called branched-chain amino
acids (BCAAs). All three are essential amino acids and
account for about 35% of the indispensable amino acids in
muscle proteins and about 40% of the preformed amino
acids required by mammals (Harper et al. 1984). These
amino acids uniquely share a common membrane trans-
port system (Hyde et al. 2003) as well as the enzymes
required for the first two steps of their catabolic systems
(Harper et al. 1984).* Correspondence: shimo@agr.nagoya-u.ac.jp
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reproduction in any medium, provided the origRecent studies have demonstrated that BCAAs, particu-
larly leucine, play an important role in the regulation of
protein metabolism, because leucine stimulates protein
synthesis by activating mammalian target of rapamycin
(mTOR) complex 1 and suppressing protein degradation
by inhibiting autophagy (Hands et al. 2009). Furthermore,
accumulating evidence indicates that BCAAs play impor-
tant roles in glucose and lipid metabolism (Nishitani et al.
2005; Doi et al. 2007; Arakawa et al. 2011; Kadota et al.
2012). Thus, BCAAs serve as medicines for treating liver
cirrhosis (Kawaguchi et al. 2011) and as sport dietary sup-
plements (Gleeson 2005). Supplementation with BCAAs
normalizes amino acid profiles, ameliorates complications
such as encephalopathy and hypoalbuminemia in patients
with liver cirrhosis (Kawaguchi et al. 2011) and helps to
reduce exercise-induced muscle damage and delayed-is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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et al. 2010).
Many studies have examined the influence of BCAAs
on plasma amino acid profiles and protein metabolism
in humans (Matthews 2005). Plasma amino-acid profiles
have received considerable clinical focus because multi-
variate indexes consisting of plasma amino acid profiles
have potential for diagnostic applications, disease activity
monitoring and the assessment of pathophysiological
conditions (Noguchi et al. 2006; Hisamatsu et al. 2012).
The initial rationale for the clinical application of plasma
amino acid profiles was Fischer’s ratio, which indicates
the balance between BCAAs and aromatic amino acids
(AAAs) and serves as a diagnostic marker and indicator
of the progression of liver fibrosis and of the effects of
drugs (Fischer et al. 1976; Soeters and Fischer 1976).
These reports generated interest in BCAAs and many
studies in humans have investigated the effects of
varying amounts and durations of infused amino acids
(Matthews 2005). Leucine infusion elevates blood leu-
cine concentrations ~6-fold from the basal level and ob-
viously decreases the concentrations of isoleucine (55%),
valine (40%), methionine (50%), phenylalanine (35%) and
tyrosine (35%) (Hagenfeldt et al. 1980). In contrast, iso-
leucine or valine infusion elevates corresponding amino
acid concentrations to ~6.5- and ~11-fold, respectively,
but do not significantly affect the concentrations of
other amino acids (Eriksson et al. 1981). These findings
indicated that leucine lowers AAA and methionine con-
centrations more effectively than other BCAAs.
On the other hand, less is known about the effects of
various oral doses of individual BCAAs than of essential
amino acid mixtures upon humans. The profiles of plasma
amino acids after ingesting amino acid supplements should
be clarified because the availability of circulating amino
acids regulates muscle protein turnover (Wolfe 2002; Bohé
et al. 2003; Drummond et al. 2010). Exercise and essential
amino acid supplements, especially those providing added
leucine, stimulate muscle protein synthesis (Pasiakos and
McClung 2011) and the plasma profiles of amino acid
concentrations after amino acid ingestion are affected
during strength training (Mero et al. 2008; 2009). Since
BCAAs are commonly included among supplements in
sports drinks, the effects of ingesting various doses of
leucine, isoleucine and valine on plasma amino acid profiles
in humans require clarification. Thus, the present study in-
vestigated the effects of ingesting 10–90 mg/kg body weight
(BW) of individual BCAAs and a mixture of BCAAs
on plasma amino acid profiles in young healthy men.
Materials and methods
Reagents
Individual BCAAs were provided by Ajinomoto Co. Inc.
(Tokyo, Japan). Heparin was purchased from MochidaPharmaceutical Co. Ltd. (Tokyo, Japan). All other reagents
were of biochemical grade and were obtained from Wako
Pure Chemical Industries Ltd. (Osaka, Japan).
Experiments
Several series of investigations into the ingestion of
individual BCAAs or mixed BCAAs proceeded between
June 2009 and September 2011. Five healthy young
males ingested 10, 20, 30, 45, 60, 75 and 90 mg/kg BW
(seven doses of individual BCAAs; 21 experiments) and 63
and 94.5 mg/kg BW of mixed BCAAs (two experiments)
and a control experiment was conducted without amino
acids. These 24 experiments proceeded in the order of
control (no amino acids), followed by the oral ingestion of
leucine, isoleucine, BCAA mixtures and valine. Low to
high doses of amino acids were investigated in the series
of experiments with individual BCAAs or BCAA mix-
tures. All experiments were conducted at intervals of at
least 1 week.
Participants
We recruited five healthy male undergraduate or gradu-
ate students at Nagoya University. After completing the
initial control and leucine ingestion experiments, only
one participant was replaced. The means ± SEM for age,
height and body weight of the participants for the initial
control and leucine ingestion experiments were 22.4 ±
0.9 years, 175 ± 2 cm and 66.6 ± 2.1 kg, respectively, and
after replacing the single participant, these values were
22.6 ± 0.6 years, 177 ± 2 cm and 67.2 ± 0.8 kg, respectively.
The absence of liver failure, diabetes or dyslipidemia was
determined in the participants from interviews and blood
tests of glucose, insulin, triglyceride, total cholesterol,
alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) levels before starting the study.
The study design, purpose and possible risks were
explained to the students, who then provided written
inform consent to participate in the present study.
The Human Research Review Committee of the Nagoya
University School of Medicine (Nagoya, Japan) approved
the study protocol.
Test drinks
Each BCAA was given to the participants in solution
(partly as a suspension) in 200 ml/60 kg BW of distilled
water at concentrations of 0.3%, 0.6%, 0.9%, 1.35%, 1.8%,
2.25% and 2.7% (w/v) for the respective doses of 10, 20,
30, 45, 60, 75 and 90 mg amino acids/kg BW. Leucine
did not fully dissolve at concentrations ≥1.8%. Test
solutions of 1.89% and 2.84% (w/v) BCAA mixtures
(weight ratio of BCAAs (Ile:Leu:Val), 1:2:1.2; Kawaguchi
et al. 2011) for the respective doses of 63 and 94.5 mg
BCAAs/kg BW were prepared in distilled water. These
corresponded to leucine doses of 30 and 45 mg/kg in a
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distilled water/60 kg.
Experimental design
The participants refrained from vigorous physical activity
or ingesting alcohol or any other fluids and consumed the
same meal (Japanese-style boxed meal) for dinner at
18:00–20:00 on the day before experiments. Thereafter,
the participants were allowed to ingest only water until
the experiment started.
On the day of experiments, participants fasted over-
night and ate one ball of rice (about 160 kcal, 90%
carbohydrate at the laboratory at 08:30) to reduce the
effects of starvation on BCAA catabolism. Blood samples
(~6 mL at 0 and 240 min; ~4 mL for time points in
between) collected about 1 h later and then at 15, 30,
45, 60, 75, 90, 105, 120, 180 and 240 min after consum-
ing a test drink containing 0–90 mg amino acid/kg BW
were immediately heparinized, cooled in ice, and then
plasma was separated by centrifugation at 4°C. Free amino
acids were analyzed in plasma samples that were deprotei-
nized with 5% (w/v) trichloroacetic acid (Noguchi et al.
2006). Deproteinized samples were stored at −80°C.
The effects of amino acid ingestion on mood states were
analyzed using the self-reporting, brief Japanese version of
the Profile of Mood States (POMS) (Yokoyama et al. 1990).
This survey is based on a 30-item mood checklist de-
signed to provide information on six mood states. The
participants evaluated the degree of each mood before
blood was collected and at 120 min after consuming the
test drink during all experiments using a rating scale from
0 (not at all) to 4 (extremely). Scores for each separate
mood state were calculated by summing the responses to
all items in each of the following subscales: tension-
anxiety, depression-dejection, anger-hostility, confusion,
fatigue and vigor.
Analyses
Free amino acid concentrations were measured using an
automated amino acid analyzer (L-8800: Hitachi, Tokyo,
Japan). Concentrations of plasma glucose (Banauch 1975),
insulin (Morgan and Lazarow 1962), free fatty acids (FFA)
(Sugo et al. 1990), total cholesterol (Richmond 1973), LDL-
cholesterol (Friedewalt 1972) and urea (Morishita et al.
1997) were measured as described at all time-points and
ALT and AST activities (Miura 1995) were measured only
at 0 and 240 min. All plasma components except amino
acids were measured at Special Reference Laboratories Inc.
(Tokyo, Japan).
Statistics
Data are expressed as means ± SEM unless otherwise
stated. Changes in the concentrations of plasma compo-
nents over time within each BCAA dose were analyzedusing a one-way repeated measures (rm) ANOVA. The
effects of BCAA intake on the profiles of plasma amino
acids and other components over time were determined
using a two-way rmANOVA (11 × 8 doses of individual
BCAAs, and 11 × 2 doses of mixed BCAAs). Significant ef-
fects of BCAA ingestion were further analyzed using
Tukey’s post-hoc test to determine significant differences
between doses. Correlations between amino acid doses and
the maximum (or minimum) concentrations (Cmax or
Cmin), and between amino acid doses and the area under
the curves (AUC) of amino acid plasma concentrations
were analyzed as described (Motulsky and Christopoulos
2004). Biphasic correlations between the two parameters
were analyzed using a standard, continuous two-phase
linear regression model. Briefly, the slopes and y-intercepts
of two-segmented lines were optimized by minimizing the
sum of the squares of the vertical distances of the points
from the lines using the Marquardt method, and the break-
point was defined as their crossing point. The likelihood of
the method was analyzed by comparing the fit with that in
a simple linear regression model using Akaike’s informa-
tion criteria. Differences in POMS scores before and after
consuming test drinks were analyzed using the Wilcoxon
signed-rank test. Differences were considered statistically
significant at P < 0.05.
Results
Effects of oral leucine on plasma amino acid profiles and
concentrations of other plasma components
Repeated-measures ANOVA
The effects of various doses of oral leucine on plasma
concentrations of free amino acids over time were statis-
tically analyzed using two-way (8 doses × 11 time points)
rmANOVA. The profiles of the three BCAAs and phenyl-
alanine were significantly affected (P < 0.001 for all three
BCAAs; P = 0.005 for phenylalanine), and that of
plasma methionine tended to be affected (P = 0.071)
by oral leucine.
Changes in the concentrations of plasma amino acids
over time within each dose of leucine were also analyzed.
The results of one-way rmANOVA showed that all doses
of leucine significantly affected the concentrations of me-
thionine, phenylalanine and tyrosine over time (Additional
file 1: Table S1), and that higher doses significantly affec-
ted those of tryptophan (Additional file 1: Table S1) and
histidine (Additional file 1: Table S2). Oral leucine did
not affect the concentrations of any other amino acids
(Additional file 1: Table S2).
Profiles of plasma BCAA concentrations
Plasma leucine concentrations remained unchanged
during the control experiment, but rapidly increased
after ingesting various doses of leucine (Additional file 1:
Table S1 and Figure 1A). The plasma concentration peaked
Figure 1 Mean changes in plasma BCAA concentrations at various time points after leucine ingestion. A, leucine; B, isoleucine; C, valine.
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and 45–90 mg/kg BW, respectively. The peak increased at
up to 45 mg leucine/kg BW. Plasma leucine concen-
trations gradually decreased after reaching a peak at all
doses, but the decline was slower at increasing doses
between 45 and 90 mg/kg BW. Plasma leucine concentra-
tions remained close to control levels at 240 min, but were
still significantly higher at doses >45 mg/kg BW compared
with controls (176 ± 16 vs.120 ± 2 μM).
Leucine ingestion gradually decreased plasma isoleucine
(Additional file 1: Table S1 and Figure 1B) and valine
(Additional file 1: Table S1 and Figure 1C) concentrations,
which reached a nadir 90–120 min later and were sus-
tained until 240 min in all experiments. Higher doses of
leucine caused more obvious effects. The levels of plasma
isoleucine and valine were the lowest at 120–240 min afterFigure 2 Correlations between ingested leucine and Cmax, Cmin and AUC o
Cmax and AUC of plasma leucine (A, B), and Cmin and AUC pf plasma isoleucine (ingesting 90 mg/kg BW of leucine, being 25% and 50% of
respective control values at the same time point.
Cmax or Cmin, and AUC of plasma amino acids
The Cmax of plasma leucine was increased by increasing
the dose of leucine up to 45 mg/kg BW and it reached a
plateau at 53 mg/kg BW (Figure 2A). Linear regression
determined from the AUC for plasma leucine concentra-
tions was biphasic in terms of leucine dose (Figure 2B).
The slope of the regression line was >2-fold higher in
the initial phase for the lower doses (0–45 mg/kg BW;
Slope = 18.4) than in the later phase for higher doses
(60–90 mg/kg BW, Slope = 7.1), and the breakpoint of
the two-segmented lines was about 52 mg/kg BW. This
breakpoint was almost the same as the dose of leucine at
which the Cmax reached a plateau.f plasma amino acid concentrations after leucine ingestion.
C, D), valine (E, F) and phenylalanine (G, H) concentrations. Arrows, breakpoints.
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respectively) of the plasma isoleucine concentration was
biphasic in terms of leucine dose. The rate at which the
plasma isoleucine concentration decreased was much
greater at the lowest dose (10 mg/kg BW) than 20–
90 mg/kg BW, indicating that the lower dose of leucine
was sufficient to decrease the plasma isoleucine concen-
tration. The breakpoints of the two-segmented line were
17 and 16 mg leucine/kg BW for the Cmin and the AUC,
respectively. These breakpoint values are much lower than
those for the Cmax and AUC of plasma leucine.
The trends for Cmin and the AUC (Figure 2E and F,
respectively) of the plasma valine concentration were the
same as those for plasma isoleucine, and the breakpoint
of the two-segmented line was 18 and 19 mg leucine/kg
BW, respectively.
The profile of changes plasma phenylalanine induced
by oral leucine were similar to that of plasma valine
(Additional file 1: Table S1), but the Cmin (Figure 2G)
and AUC (Figure 2H) of the plasma phenylalanine con-
centration remained essentially constant at doses of 30–
90 mg/kg BW. The lowest level of plasma phenylalanine
was about 67% of controls. The breakpoint of the two-
segmented line was 24 mg leucine/kg BW for both Cmin
and AUC.
Concentrations of other plasma components
The concentrations of plasma components other than
amino acids over time were not significantly affected by
leucine (Additional file 2: Online Resource 1). Although
changes in plasma glucose, insulin and FFA concentra-
tions over time within each leucine dose were significant
in the analyses with the one-way rmANOVA, changes
were also similarly time-dependent after vehicle ingestion.
Effects of isoleucine ingestion on plasma amino acid
profiles and concentrations of other plasma components
Repeated-measures ANOVA
The results of statistical analyses using two-way (8 doses ×
11 time points) rmANOVA showed that oral isoleucine
significantly (P < 0.001) affected only the plasma isoleucine
profile. One-way rmANOVA showed that all doses of iso-
leucine significantly affected the plasma concentrations of
leucine, isoleucine and methionine over time, although
the changes in plasma leucine and methionine concentra-
tions were quite minimal (Additional file 1: Table S3). The
concentrations of other amino acids were essentially
unaffected by oral isoleucine (Additional file 1: Table S4).
Profiles of plasma BCAA concentrations
Various doses of oral isoleucine increased plasma iso-
leucine concentrations (Additional file 1: Table S4 and
Figure 3A). The plasma concentration of isoleucine
peaked at 30 min after ingesting 10–60 mg/kg BW ofisoleucine, similarly to that of plasma leucine con-
centrations after ingesting leucine, and at 45 min after
ingesting 75–90 mg/kg BW. The plasma isoleucine peaks
were elevated with increasing doses of isoleucine up to
90 mg/kg BW. Plasma isoleucine concentrations gradually
declined after reaching a peak at all ingested doses, but
more slowly than the plasma leucine concentration after
leucine ingestion; plasma isoleucine and leucine con-
centrations were >6-fold and 1.4-fold, respectively, of the
base at 240 min after the highest dose (90 mg/kg BW) of
corresponding amino acid ingestion. All tested doses of
isoleucine had apparently minor effects on plasma
leucine (Additional file 1: Table S3, Figure 3B) and valine
(Additional file 1: Table S3, Figure 3C) concentrations
over time.
These results indicate that plasma amino acid profiles
were much less affected by oral isoleucine than by oral
leucine.
Cmax and AUC of the plasma isoleucine concentrations
In contrast to leucine, the Cmax (Figure 4A) and AUC
(Figure 4B) of the plasma isoleucine concentrations linearly
correlated with doses of isoleucine without a breakpoint.
Concentrations of other plasma components
Various doses of oral isoleucine, like leucine, did not
affect the concentrations of other plasma components
over time (Additional file 2: Online Resource 2).
Effects of valine ingestion on plasma amino acid profile
and concentrations of other plasma components
Repeated-measures ANOVA
Statistical analyses using two-way (8 doses × 11 time
points) rmANOVA showed that valine ingestion sig-
nificantly affected only the profile of plasma valine
(P < 0.001). One-way rmANOVA showed that changes in
the concentrations of plasma amino acids, except for
valine, over time within each dose of valine were essen-
tially not significant (Additional file 1: Table S5 and S6).
Profiles of plasma BCAA concentrations
Various doses of oral valine increased the concentrations
of plasma valine to peak at 30–45 min after ingesting
10–90 mg/kg BW (Additional file 1: Table S5, Figure 5A).
However, peaks for plasma valine after valine ingestion
were much higher than those for plasma isoleucine after
isoleucine ingestion at the same doses, reaching 1035 ±
28 μM at 240 min at the highest ingested dose of valine.
Peak plasma valine concentrations then declined more
slowly than those of leucine and isoleucine. The vari-
ous doses of valine apparently had minimal effects on
plasma leucine and isoleucine concentrations over
time (Figure 5B and C respectively, and Additional
file 1: Table S5).
Figure 3 Mean changes in plasma BCAA concentrations at various time points after isoleucine ingestion. A, isoleucine; B, leucine; C, valine.
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Figure 4 Correlations between ingested isoleucine and valine with Cmax or AUC of respective plasma amino acid concentration.
Cmax and AUC of plasma isoleucine (A, B) and valine (C, D) concentrations after ingesting isoleucine and valine, respectively.
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amount of changes in plasma amino acid profiles among
the three BCAAs.
Cmax and AUC of plasma valine concentrations
The Cmax and AUC (Figure 4C and D, respectively) of
the plasma valine concentration linearly correlated with
valine dose, similarly to that of the plasma isoleucine
concentration after isoleucine ingestion.
Concentrations of other plasma components
The tested doses of valine, like leucine and isoleucine,
did not alter the concentrations of plasma components
other than amino acids over time (Additional file 2:
Online Resource 3).
Effects of mixed BCAAs on plasma amino acid profiles
and concentrations of other plasma components
Repeated-measures ANOVA and profiles of plasma BCAA
concentrations
We examined the effects of 63 and 94.5 mg/kg BW of
mixed BCAA (including 30 and 45 mg/kg BW of leu-
cine, respectively) on plasma amino acid profiles. Sta-
tistical analyses using two-way (3 doses × 11 time points)
rmANOVA showed that mixed BCAA doses significantly
(P < 0.001) affected the profiles of plasma leucine, isoleu-
cine, valine, phenylalanine and tyrosine. Plasma BCAA
levels peaked at 30–45 min (leucine and isoleucine) and
at 45–60 min (valine) after ingesting the mixed BCAAs(Additional file 1: Table S7). Thus, the levels peaked
somewhat later compared with individual BCAA inges-
tion. Plasma concentrations of isoleucine and valine after
the peak (Additional file 1: Table S7) declined more rap-
idly than after ingesting either alone (Additional file 1:
Table S3 and S5, respectively), suggesting that the in-
creased plasma concentrations of leucine promoted the
decline of isoleucine and valine concentrations that were
increased by ingesting mixed BCAAs. These results are
supported by the findings that the decline in peak
plasma isoleucine and valine concentrations after ingest-
ing the respective BCAA was much slower than that of
plasma leucine after ingesting leucine. The concentra-
tions of other amino acids were essentially unaffected by
oral mixed BCAAs (Additional file 1: Tables S7 and S8).Concentrations of other plasma components
The tested doses of mixed BCAAs, like individual BCAAs,
did not change the concentrations of plasma components
other than amino acids over time (Additional file 2:
Online Resource 4).POMS scores
Table 1 shows that the POMS scores obtained before
and at 2 h after ingesting maximal doses of individual
BCAAs and the BCAA mixtures did not significantly
differ, indicating that mood states were not significantly
affected. In addition, none of the participants indicated
Figure 5 Mean changes in plasma BCAA concentrations at various time points after valine ingestion. A, valine; B, leucine; C, isoleucine.
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Table 1 POMS scores in the maximal doses of individual BCAAs and mixed BCAA ingestion
Amino acid ingested Mood Before ingestion 2 h after ingestion P value
Basal
Tension - anxiety 0.2 ± 0.1 1.4 ± 0.6 0.66
Depression - dejection 0.8 ± 0.4 0.6 ± 0.3 0.66
Anger - hostility 0.8 ± 0.4 0.8 ± 0.4 1.00
Confusion 2.6 ± 1.2 2.0 ± 0.9 0.59
Fatigue 3.6 ± 1.6 3.4 ± 1.5 0.79
Vigor 6.2 ± 2.8 2.6 ± 1.2 0.07
Leu 90 mg/kg BE
Tension - anxiety 0.8 ± 0.4 0.2 ± 0.1 0.32
Depression - dejection 0.4 ± 0.2 0.2 ± 0.1 0.32
Anger - hostility 0.0 ± 0.0 0.0 ± 0.0 1.00
Confusion 1.6 ± 0.7 0.6 ± 0.3 0.32
Fatigue 3.6 ± 1.6 3.0 ± 1.3 0.18
Vigor 6.2 ± 2.8 6.6 ± 3.0 0.59
Ile 90 mg/kg BW
Tension - anxiety 0.0 ± 0.0 0.0 ± 0.0 1.00
Depression - dejection 0.0 ± 0.0 0.0 ± 0.0 1.00
Anger - hostility 0.4 ± 0.2 0.0 ± 0.0 0.32
Confusion 0.2 ± 0.1 0.0 ± 0.0 0.32
Fatigue 2.4 ± 1.1 2.0 ± 0.9 0.16
Vigor 8.4 ± 3.8 9.0 ± 4.0 0.41
Val 90 mg/kg BW
Tension - anxiety 0.0 ± 0.0 0.0 ± 0.0 1.00
Depression - dejection 0.0 ± 0.0 0.0 ± 0.0 1.00
Anger - hostility 0.0 ± 0.0 0.2 ± 0.1 0.32
Confusion 0.6 ± 0.3 0.2 ± 0.1 0.32
Fatigue 2.0 ± 0.9 1.8 ± 0.8 0.32
Vigor 10.6 ± 4.7 10.4 ± 4.7 0.32
Mixed BCAA 94.5 mg/kg BW
Tension - anxiety 0.0 ± 0.0 0.0 ± 0.0 1.00
Depression - dejection 0.0 ± 0.0 0.0 ± 0.0 1.00
Anger - hostility 0.0 ± 0.0 0.0 ± 0.0 1.00
Confusion 0.0 ± 0.0 0.2 ± 0.1 0.32
Fatigue 1.6 ± 0.7 1.4 ± 0.6 0.32
Vigor 11.0 ± 4.9 11.2 ± 5.0 1.00
Values are means ± SE.
Statistic analyses were performed by the Wilcoxon signed-rank test.
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in accordance with the POMS scores.
Discussion
The present study found that a bolus ingestion of
10–90 mg/kg BW of leucine significantly decreased
plasma concentrations of isoleucine, valine and phenyl-
alanine and tended to decrease those of methionine and
tyrosine. Furthermore, the bolus ingestion of isoleucine or
valine did not cause such effects. These findings are
largely consistent with those of studies of individual
BCAA infusions (Hagenfeldt et al. 1980; Eriksson et al.
1981) and of mixed BCAA ingestion (Shimomura et al.
2009; Zhang et al. 2011). However, we discovered thatleucine at doses as low as 10–20 mg/kg BW can effectively
decrease plasma levels of isoleucine, valine and phenyl-
alanine. Furthermore, the rate at which the peak plasma
BCAA concentrations declined obviously differed between
with the presence and absence of leucine ingestion, sug-
gesting that plasma leucine is a potent regulator of the
plasma concentrations of BCAAs, methionine and AAAs.
Individual BCAA intake increased corresponding plasma
BCAA concentrations, which peaked around 30 min later.
However, the heights of the peaks in response to the tested
doses of individual BCAAs differed between leucine and
other BCAAs. Plasma leucine levels after leucine inges-
tion reached a plateau (at about 800 μM) after ingesting at
53 mg leucine/kg BW, whereas plasma isoleucine and
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dose-dependently increased up to 90 mg/kg BW. These
results suggest that the absorption rate of leucine from the
gut into the circulation reached a plateau at a dose of
53 mg/kg BW, although the capacity for leucine in human
plasma appears to be much higher (about 2000 μM), as
determined by a study that identified the tolerable upper
intake level of leucine in young men (Elango et al. 2012).
This phenomenon might be associated with the solubility
of leucine, which did not completely dissolve at doses
of >60 mg/kg BW in test drinks. This property of
leucine also reflects the biphasic linear regression of the
increase in the rate of the AUC of the plasma leucine
concentration in response to dose with a breakpoint at
about 52 mg/kg BW.
The increasing plasma leucine concentration peaked at
around 30 min after ingestion and then plasma con-
centrations of other BCAAs decreased. The ingestion of
90 mg leucine/kg BW caused plasma isoleucine and
valine concentrations to fall to around 25% and 50% of
respective control values and remain at these levels for
at least 4 h. All three BCAAs share the first two enzymes
in their catabolic systems and branched-chain α-keto
derived from leucine, but not from isoleucine or
valine, promotes BCAA catabolism by activating the
second enzyme (branched-chain α-keto acid dehydro-
genase (BCKDH) complex) in the catabolic system of rat
muscle and liver via inhibition of BCKDH kinase, which is
responsible for inactivation of the complex by phosphory-
lation (Paxton and Harris 1984; Hood and Terjung 1987;
Fujii et al. 1994; Ishiguro et al. 2006). Thus, promoting
BCAA degradation might have contributed to the de-
creases in plasma isoleucine and valine levels. On the
other hand, the consumption of free amino acids required
for protein synthesis after ingesting leucine in amounts up
to ≤90 mg/kg BW appeared to have essentially no effect
on plasma amino acid profiles, like the concentrations of
other essential amino acids such as lysine and threonine.
This result is consistent with the fact that the leucine spe-
cifically induces a reduction in protein breakdown without
increasing protein synthesis in humans (Matthews 2005),
although leucine administration stimulates protein synthe-
sis in the tissues of other animals (Proud 2007).
On the other hand, human muscle protein synthesis is
enhanced by exercise (especially resistance exercise)
during the post-exercise recovery period, and protein
synthesis is greatly stimulated by resistance exercise
combined with essential amino acid ingestion (Walker
et al. 2011). The timing of essential amino acid supple-
mentation in relation to exercise is important to stimu-
late human skeletal muscle protein synthesis; ingestion
of a solution of essential amino acids and carbohydrate
after, but not before, resistance exercise maximally
stimulates muscle protein synthesis during recovery afterexercise (Drummond et al. 2009; Fujita et al. 2009).
Leucine is a key amino acid in the anabolic response of
skeletal muscle to essential amino acids (Drummond
et al. 2009; Pasiakos and McClung 2011).
Branched-chain amino acids are used as medicines to
treat liver cirrhosis (Kawaguchi et al. 2011). The BCAA:
AAA ratio plays a causative role (Bianchi et al. 2005;
Dejong et al. 2007) in hepatic encephalopathy, and pro-
viding BCAA supplements to patients with liver cirrho-
sis ameliorates hepatic encephalopathy (Holecek 2010).
This effect of BCAA supplementation might, at least in
part, be explained by the leucine-induced decrease in
plasma concentrations of AAAs, which might be incor-
porated into body tissues from the circulation.
Although the elevation of plasma leucine concentrations
induced considerably lower concentrations of plasma iso-
leucine and valine, the mood states of the study parti-
cipants determined by POMS were not affected by oral
leucine at any dose, thus suggesting that the temporal pro-
files of plasma amino acids induced by leucine ingestion
do not affect amino acid status in the brains of healthy
men. This is consistent with the findings of a study of
up to 1250 mg/kg BW/day of oral leucine to determine
tolerable maximal intake (Elango et al. 2012). Mixtures of
BCAAs are popular dietary supplements among athletes
and are also used as medicines for patients with liver
cirrhosis; many of the physiological effects of BCAAs can
be attributed to the action of leucine. However, since
information about the physiological effects of an altered
plasma amino acid balance remains limited, leucine should
not be ingested alone to avoid temporal disruption of the
plasma BCAA balance. Mixtures of BCAAs can be recom-
mended as a safe dietary sports supplement or medicine.Additional files
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